In breast cancer, FMRP catalyzes N6-methyladenosine (m6A) modification of Solute Carrier Family 7 Member 11 (SLC7A11) mRNA and interacts with Heterogeneous Nuclear Ribonucleoprotein M (hnRNPM) to mediate SLC7A11-S splicing, promoting ferroptosis resistance [95]. This evidence concerns the gene SLC7A11 and breast carcinoma.